Clinical Features of Hypersensitivity Reactions to Carboplatin

Markman, Maurie; Kennedy, Alexander W.; Webster, Kenneth; Elson, Paul; Peterson, Gertrude; Kulp, Barbara; Belinson, Jerome L.

doi:10.1200/jco.1999.17.4.1141

Cited by 331 publications

(301 citation statements)

References 18 publications

Supporting

Mentioning

273

Contrasting

Unclassified

Order By: Relevance

“…It is not surprising that after the introduction of platinum compounds into chemotherapy, their association with type I hypersensitivity reactions was confirmed (Cleare et al, 1976). These reactions were first described for CDDP with a 5 -20% incidence (Wiesenfeld et al, 1979;Shleback et al, 1995;Ö zgüroglu et al, 1999), and evidence regarding similar reactions for CBDCA are also available (Planner et al, 1991;Morgan et al, 1994;Weideman et al, 1994;Markman et al, 1999).…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Hypersensitivity reactions related to oxaliplatin (OHP)

et al. 2003

View full text Add to dashboard Cite

Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions related to oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected by advanced colorectal cancer were treated with different schedules containing OHP, at the Institute of Haematology and Medical Oncology 'L. and A. Seragnoli' of Bologna and at the Medical Oncology Division of Livorno Hospital. Seventeen patients (13%) showed hypersensitivity reactions after a few minutes from the start of the OHP infusion. Usually, these reactions were seen after 2 -17 exposures to OHP (Mean7s.e.: 9.471.07). No patient experienced allergic reactions at his/her first OHP infusion. Eight patients developed a mild reaction consisting of flushing and swelling of the face and hands, itching, sweating and lachrymation. The remaining nine patients showed a moderatesevere reaction with dyspnoea, wheezing, laryngospasm, psycho-motor agitation, tachycardia, precordial pain, diffuse erythema, itching and sweating. Six patients out of 17 were re-exposed to the drug with premedication of steroids and all except one developed the hypersensitivity reaction again. The cumulative dose, the time of exposure to OHP and the clinical features are variable and unpredictable. The risk of developing hypersensitivity reactions in patients treated with a short infusion of OHP cannot be underestimated.

show abstract

Section: Discussionmentioning

confidence: 97%

“…For other platinum compounds, this kind of reaction is well known (Cleare et al, 1976;Wiesenfeld et al, 1979;Planner et al, 1991;Morgan et al, 1994;Weideman et al, 1994;Shleback et al, 1995;Markman et al, 1999;Ö zgüroglu et al, 1999). On data sheets of OHP, these clinical features are not stressed.…”

mentioning

confidence: 99%

Hypersensitivity reactions related to oxaliplatin (OHP)

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Although five patients stopped because of cumulative toxicity, three of these were from the previously well-described allergic reactions to carboplatin occurring after many courses. 33 Consistent with the American Society of Clinical Oncology treatment guidelines, at the time this study opened it was not the standard practice to treat beyond six or eight courses with frontline platinum doublets at UT M. D. Anderson Cancer Center. More recent recommendations are that patients without response should be treated with four cycles and no more than six cycles in patients with response.…”

Section: Discussionmentioning

confidence: 99%

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

Zinner

Fossella

Gladish

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe primary objectives of this study were to determine the efficacy and tolerability of a pemetrexed‐carboplatin combination as first‐line therapy in patients with advanced nonsmall cell lung cancer.METHODSEligibility criteria included Zubrod performance status of 0 or 1, Stage IIIB (malignant effusion) or IV disease, and no prior chemotherapy. Treatment was pemetrexed 500 mg/m2 given intravenously and carboplatin area under the serum concentration–time curve = 6 given intravenously on Day 1 every 3 weeks for six cycles; patients could receive additional cycles at the discretion of the treating physician and patient. All patients received folic acid, vitamin B12, and dexamethasone prophylaxis.RESULTSFifty patients (31 men and 19 women) were treated. The median age was 62 years. Ninety‐six percent of patients had Stage IV disease, and 88% had a performance status of 1. The median number of cycles was 6; 15 patients received 8 or more cycles. There was Grade 3/4 neutropenia in 11 (22%) and 2 (4%) patients, respectively; Grade 3/4 thrombocytopenia in 1 (2%) and 0 patients, respectively. Three patients (6%) experienced Grade 3 nonhematologic side effects (diarrhea, neutropenic pneumonia, and fatigue). No patients had sensory neuropathy or alopecia >Grade 1. The partial response rate was 24%, median time to progression 5.4 months, 1‐year survival 56.0%, and median survival 13.5 months.CONCLUSIONSThis is an active, very well‐tolerated regimen. Trials focused on how to integrate this doublet with novel agents are warranted. Cancer 2005. © 2005 American Cancer Society.

show abstract

“…A recent study at the Cleveland Clinic Cancer Center [22] reported that hypersensitivity to carboplatin developed in 12% of carboplatin-treated patients. Because of the possibility of fatal cross-hypersensitivity, the use of cisplatin in patients who have developed hypersensitivity to carboplatin is not recommended [23].…”

Section: Platinum Agentsmentioning

confidence: 99%

Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

Dunton

2002

The Oncologist

View full text Add to dashboard Cite

Recognition of recurrent ovarian cancer as a disease with significant secondary responses and remissions has led to an increase in the need for oncologists to plan for the long-term therapy of patients. However, many of the currently available front-line and salvage agents used in advanced ovarian cancer are associated with cumulative and/or irreversible toxicities that pose challenges in longterm planning. The irreversible effects associated with some of these therapies may render patients less tolerant to subsequent treatments and lead to a cycle of diminishing treatment options with each remission and disease relapse. Additionally, the potential for patients to experience cumulative toxicity must be carefully weighed against the goals of prolonging the disease-free interval and improving patient quality of life. A number of agents are available in the treatment armamentarium (platinum, paclitaxel, gemcitabine, etoposide, liposomal doxorubicin, and topotecan), many, but not all of which are associated with cumulative toxicity. For instance, cumulative neurotoxicity associated with cisplatin as first-line therapy may diminish the option for retreatment with platinum at first relapse. In contrast, the main toxicity associated with topotecan is noncumulative, manageable myelosuppression. In this review, the major toxicities associated with the predominant chemotherapy agents used in advanced ovarian cancer are discussed along with selected management approaches in the context of long-term treatment planning and sequencing.

show abstract

Clinical Features of Hypersensitivity Reactions to Carboplatin

Cited by 331 publications

References 18 publications

Hypersensitivity reactions related to oxaliplatin (OHP)

Hypersensitivity reactions related to oxaliplatin (OHP)

Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer

Management of Treatment-Related Toxicity in Advanced Ovarian Cancer

Contact Info

Product

Resources

About